Mod GRF 1-29 vs CJC-1295

These two molecules share the same backbone — both are 30-amino-acid modified GHRH(1-29) analogs — and the difference is whether the molecule is conjugated to a Drug Affinity Complex (DAC) that binds it to serum albumin and dramatically extends its half-life. Mod GRF 1-29 is the no-DAC version with a half-life measured in minutes; CJC-1295 in its commonly-discussed form includes the DAC and has a half-life measured in days. Same molecule, completely different cadence.

Pulse versus tonic exposure is the structural consequence. Mod GRF 1-29 produces a sharp, short GH pulse that resembles the body's natural overnight pattern — typically administered pre-bed in the published protocols, often paired with a GHRP for a coordinated pulse from both sides of the pathway. CJC-1295 with DAC produces sustained GH elevation rather than a discrete pulse, which is the trade-off the DAC modification was designed for. Researchers who prioritize preserving pulsatility tend to log Mod GRF; researchers who prioritize convenience and cumulative exposure tend to log CJC-1295.

Cadence is the most-tracked difference in side-by-side logs. Mod GRF 1-29 protocols are written around once-or-twice-daily administration; CJC-1295 with DAC protocols sit at twice-weekly or even weekly. A 5 mg vial of Mod GRF dosed daily empties in roughly the same calendar window that a 5 mg vial of CJC-1295 with DAC stretches across months — the vial-duration calculator linked below shows the gap at your own example vials.

Reconstitution is identical between the two molecules and the unit math on a 100-unit syringe is in the same range at typical vial sizes. The mg-to-units calculator linked below handles either once vial concentration is set. The most common confusion in research-peptide logs is which version is in the vial when the label just reads CJC-1295 — the DAC-versus-no-DAC distinction is the entire reason the cadence question has two right answers depending on which molecule you actually have.

For the Mod GRF 1-29 vs CJC-1295 decision specifically, the calendar shape is what most readers underweight. Mod GRF 1-29's example vial is 2 mg drawn against 0.1 mg per dose at 21 doses per week. CJC-1295's example vial is 2 mg drawn against 0.1 mg per dose at 7 doses per week. Those four numbers feed every column in the table above; change any one and the mod grf 1 29 vs cjc 1295 comparison shifts with it.

Concentration in this pair: Mod GRF 1-29 sits at 1.00 mg/mL on the example reconstitution; CJC-1295 sits at 1.00 mg/mL on its example. That single ratio is what determines how many U-100 syringe units a given dose of either molecule actually draws, so it is the first thing to confirm before treating any "Mod GRF 1-29 vs CJC-1295" unit number on the internet as authoritative.

Doses per vial in this matchup work out to roughly 20 for Mod GRF 1-29 and 20 for CJC-1295 at the example dose sizes, with vial-duration windows near 1.0 weeks and 2.9 weeks respectively. Refill cadence follows directly from those windows, which is why the mod grf 1 29 vs cjc 1295 pair shows up in planning conversations more than in pure mechanism conversations.

When readers compare Mod GRF 1-29 against CJC-1295, the Mod GRF 1-29-side mistakes that show up most in logs are: Using the peptide without being on an empty stomach, which can blunt the growth hormone release. Confusing Mod GRF 1-29 with the long-acting CJC-1295 with DAC and using an incorrect, infrequent dosing schedule. Storing the reconstituted (mixed) vial at room temperature instead of in the refrigerator. Vigorously shaking the vial when mixing, which can destroy the fragile peptide bonds. Each of these gets amplified when a reader is also actively comparing against CJC-1295, because muscle memory from one molecule's unit math leaks into the other.

Mod GRF 1-29 question worth answering up front — What's the difference between Mod GRF 1-29 and CJC-1295 with DAC? The key difference is the half-life. Mod GRF 1-29 (also called CJC-1295 without DAC) is short-acting, lasting about 30 minutes. The 'with DAC' version has a molecule attached that lets it bind to proteins in the blood, extending its half-life to over a week. This means Mod GRF 1-29 creates short GH pulses, while CJC-1295 with DAC creates a long, sustained elevation of GH.

Mod GRF 1-29 question worth answering up front — Why do people stack Mod GRF 1-29 with Ipamorelin? People use these two together to create a stronger GH pulse. Mod GRF 1-29 and Ipamorelin work on two different receptors in the pituitary gland. Stimulating both pathways at once results in a synergistic effect, causing a much larger release of growth hormone than either peptide could on its own.

On the CJC-1295 side of the Mod GRF 1-29 vs CJC-1295 decision, the recurring mistakes are: Applying a daily dosing frequency appropriate for the no-DAC variant to the long-acting DAC variant. Logging a co-administered dose of CJC-1295 (no-DAC) and ipamorelin as a single combined entry, which desynchronizes per-vial inventory tracking. Failing to explicitly document whether the 'with DAC' or 'no-DAC' version was used, rendering the log data ambiguous and difficult to interpret later. Confusing the terminology and assuming 'Mod GRF 1-29' is a completely different compound rather than the specific name for CJC-1295 without DAC. These are not generic dosing slips — they are the ones that compound when CJC-1295 is being logged in parallel with Mod GRF 1-29.

CJC-1295 question worth answering up front — What is the functional difference between CJC-1295 with DAC and without DAC? The primary difference is the half-life and resulting dosing schedule. The DAC (Drug Affinity Complex) allows the peptide to bind to albumin in the blood, extending its half-life to about 6-8 days and enabling weekly or twice-weekly administration. The no-DAC version has a half-life of only about 30 minutes, requiring daily or multiple daily administrations to be studied.

CJC-1295 question worth answering up front — Why is CJC-1295 without DAC frequently paired with ipamorelin in research? This combination creates a synergistic effect by stimulating the pituitary gland through two separate pathways. CJC-1295 without DAC is a GHRH analog that stimulates the GHRH receptor, while ipamorelin is a ghrelin mimetic that stimulates the ghrelin receptor (GHSR). Activating both receptors at once results in a much larger release of growth hormone than stimulating either one alone.